Document is current

Article History

Received: 12 November 2024

Accepted: 6 December 2024

First Online: 6 January 2025

Declarations

:

: G.L.B. reported personal fees from Abbott and Stryker, outside the submitted work. G.M. reports consulting agreements with Boston Scientific. L. K. reports financial interest in Neuros, Nevro, Biotronik, Nalu, Medtronic, Xalud, Saul Therapeutics, Saluda Medical, NeuraLace, Gimer Medical, and Avanos; is a member of the scientific advisory board for Presidio, Saluda Medical, and Biotronik; Paid Speaker for Nevro and Saluda Medical. The authors report no other conflicts of interest in this work. P. S. reports grants from Saluda, Nalu, AIS Therapeutics, Thermaquil, Biotronik, electroCore and Vertos, outside the scope of this work; royalties from the Averitas-Qutenza Patch, outside the scope of this work; payment or honoraria from Medtronic and SPR Therapeutics, outside the scope of this work; patents for vagus nerve and topical capsaicin products; participation in a Data Safety Monitoring or Advisory Board for Nalu and Saluda; a leadership role in the World Institute of Pain, American Society of Pain and Neuroscience, American Society of Interventional Pain Physicians, and the Florida Academy of Pain Management; and stock options in Saluda, Nalu and electroCore.